Global Manufacturing
It has 8 manufacturing sites built following ICH guidelines from product design to facility construction.
It has 7 manufacturing sites in China conforming to international standards.
It has 1 manufacturing site in Germany, which is one of the largest independent manufacturing sites in Europe producing transdermal drug delivery systems.
Global R&D
The group has R&D centers in China,
the U.S. and Europe.
Its robust pipeline includes 20+ drug candidates under development in China
and 10+ drug candidates under development abroad, including the U.S., Europe and Japan.
Global Market
The group has key products in the CNS, oncology,
cardiovascular and other therapeutic areas.
From 2021 to 2024,it had a total of 13 new drugs
approved for marketing in the U.S., several European
countries, and China.
It conducts business in over 80 countries and regions around the world, including major pharmaceutical markets like China,the U.S., Europe, and Japan, as well as some fast-growing emerging markets.
Culture

Mission
Advanced Technologies for
Better Quality of Life

Vision
To Be a Leading Global
Pharmaceutical Company

Business Philosophy
Customer Focus, Operational Excellence, Employee Development

Core Values
Integrity, Cooperation, Innovation, Excellence

History
- 1994The establishment of Luye Pharma
- 1998Established Intellectual Property Dept. and International Cooperation Dept. to pursue international development
- 1999
Established an R&D Center, systematically building drug research and development capabilities
The new GMP standard plant started operations, employing an international quality management system
- 2007Acquired Nanjing Kanghai, Nanjing Sike and Beijing WBL Peking University Biotech, strengthening the oncology and cardiovascular portfolios
- 2011
Acquired Sichuan Baoguang, strengthening its business in the endocrine and metabolism fields
- 2013
Topical/Oral Preparation Workshop passed EU GMP inspections
Multiple new drugs in the CNS field were registered and undergoing clinical trials in the U.S., to drive the global R&D strategy
- 2014Listed on the main board of the Hong Kong Stock Exchange, speeding up the global strategy
- 2016
Acquired the transdermal drug delivery system business of a Swiss pharmaceutical company Acino, expanding operations to major international markets including Europe and the U.S.
- 2018
Acquired AstraZeneca's Seroquel and Seroquel XR in 51 countries and regions, accelerating the creation of a global commercial network
- 2019
Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets
Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from this innovative therapy
- 2020Acquired Boan, accelerating development in the field of biopharmaceuticals
- 2021Began to reap the benefits of R&D with the approval of Ruiketuo (risperidone microspheres for injection (II)) and Boyounuo (bevacizumab injection) in China, and Rivastigmine Twice Weekly Transdermal Patch in several European countries.
- 2022
Boan Biotech was listed on the Main Board of the Hong Kong Stock Exchange, accelerating its journey towards becoming a leading global biopharmaceutical company.
Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets) and Boyoubei (denosumab injection 60mg) were approved for marketing in China.
- 2023Four investigational drugs were approved for marketing, including Rykindo (risperidone) for extended-release injectable suspension in the U.S., Baituowei (goserelin microspheres for injection) in China, and Lurbinectedin in China’s Hong Kong SAR and Macao SAR.
- 2024Six investigational drugs were approved for marketing, including Boluojia (denosumab injection 120mg), Meibirui (paliperidone palmitate injection), Jinyouping (rotigotine microspheres for injection), Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) were approved for marketing in China; Erzofri (paliperidone palmitate) extended-release injectable suspension was approved for marketing in the U.S.
History
- 1994The establishment of Luye Pharma
- 1998Established Intellectual Property Dept. and International Cooperation Dept. to pursue international development
- 1999Established an R&D Center, systematically building drug research and development capabilities
The new GMP standard plant started operations, employing an international quality management system - 2007Acquired Nanjing Kanghai, Nanjing Sike and Beijing WBL Peking University Biotech, strengthening the oncology and cardiovascular portfolios
- 2011
Acquired Sichuan Baoguang, strengthening its business in the endocrine and metabolism fields
- 2013
Topical/Oral Preparation Workshop passed EU GMP inspections
Multiple new drugs in the CNS field were registered and undergoing clinical trials in the U.S., to drive the global R&D strategy
- 2014Listed on the main board of the Hong Kong Stock Exchange, speeding up the global strategy
- 2016
Acquired the transdermal drug delivery system business of a Swiss pharmaceutical company Acino, expanding operations to major international markets including Europe and the U.S.
- 2018
Acquired AstraZeneca's Seroquel and Seroquel XR in 51 countries and regions, accelerating the creation of a global commercial network
- 2019
Collaborated with AstraZeneca to promote high-quality TCM product- Xuezhikang to China and global markets
Licensed by PharmaMar to develop Lurbinectedin in China, enabling Chinese patients to benefit from this innovative therapy
- 2020Acquired Boan, accelerating development in the field of biopharmaceuticals
- 2021Began to reap the benefits of R&D with the approval of Ruiketuo (risperidone microspheres for injection (II)) and Boyounuo (bevacizumab injection) in China, and Rivastigmine Twice Weekly Transdermal Patch in several European countries.
- 2022
Boan Biotech was listed on the Main Board of the Hong Kong Stock Exchange, accelerating its journey towards becoming a leading global biopharmaceutical company.
Ruoxinlin (toludesvenlafaxine hydrochloride sustained-release tablets) and Boyoubei (denosumab injection 60mg) were approved for marketing in China.
- 2023Four investigational drugs were approved for marketing, including Rykindo (risperidone) for extended-release injectable suspension in the U.S., Baituowei (goserelin microspheres for injection) in China, and Lurbinectedin in China’s Hong Kong SAR and Macao SAR.
- 2024Six investigational drugs were approved for marketing, including Boluojia (denosumab injection 120mg), Meibirui (paliperidone palmitate injection), Jinyouping (rotigotine microspheres for injection), Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) were approved for marketing in China; Erzofri (paliperidone palmitate) extended-release injectable suspension was approved for marketing in the U.S.


Responsibility
We are dedicated to becoming a leading global pharmaceutical company. We have both clear business goals and ambitious social objectives as part of the vision we want to realize. We are concerned about the environment, support education, encourage innovation, care about patients and serve the community. We aim to actively fulfill our corporate social responsibility and serve the community wholeheartedly while doing business.
Environmental Policy, Objectives and Commitments
EHS policy: Focus on environment, health and safety to ensure sustainable development.
EHS objectives: Ensuring the integrated management system of environmental and occupational health and safety running in a normal way and improving it continuously.
EHS commitments: Maintain the management system, take effective measures for continuous improvement, and correct and prevent any deviation from the environmental and occupational health and safety policy, and environmental and occupational health and safety objectives.
To ensure that all the employees strictly follow the company's environmental and occupational health and safety policy, objectives and commitments, with first-class management, quality products and satisfactory service to continuously provide high-tech products to serve the market.
Environmental Policy, Objectives and Commitments
EHS policy: Focus on environment, health and safety to ensure sustainable development.
EHS objectives: Ensuring the integrated management system of environmental and occupational health and safety running in a normal way and improving it continuously.
EHS commitments: Maintain the management system, take effective measures for continuous improvement, and correct and prevent any deviation from the environmental and occupational health and safety policy, and environmental and occupational health and safety objectives.
To ensure that all the employees strictly follow the company's environmental and occupational health and safety policy, objectives and commitments, with first-class management, quality products and satisfactory service to continuously provide high-tech products to serve the market.

